是的,观注此药很久了
貌似6月在美国发售,一年的药费在13000美元左右。
Development History and FDA Approval Process for Nuplazid
Date
Article
Apr 29, 2016 Approval FDA Approves Nuplazid (pimavanserin) for Parkinson’s Disease Psychosis
Mar 29, 2016 FDA Advisory Committee Votes 12 to 2 That Benefits of Nuplazid (Pimavanserin) for the Treatment of Psychosis Associated with Parkinson’s Disease Outweigh the Risks
Nov 2, 2015 Acadia Pharmaceuticals Announces FDA Priority Review of Nuplazid (Pimavanserin) NDA for Parkinson’s Disease Psychosis
Sep 3, 2015 Acadia Pharmaceuticals Submits NDA for Nuplazid for the Treatment of Parkinson’s Disease Psychosis
Mar 21, 2013 ACADIA Announces Presentation of Data from Its Pivotal Phase III Parkinson’s Disease Psychosis Study with Pimavanserin at the American Academy of Neurology Annual Meeting
Nov 27, 2012 ACADIA Announces Pimavanserin Meets Primary and Key Secondary Endpoints in Pivotal Phase III Parkinson’s Disease Psychosis Trial
本贴相关图片: